1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
149.95 USD   +4.97%
07/01INSIDER SELL : Moderna
06/30Moderna Files For Canadian Regulatory Approval Of New COVID-19 Booster
06/30U.S. FDA to use existing Omicron booster data to review shots targeting new subvariants -official
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

As COVID cases rise, U.S. health officials mull widening additional booster eligibility

05/18/2022 | 12:20pm EDT

WASHINGTON, May 18 (Reuters) - Health officials are considering extending the eligibility for a second COVID-19 vaccine booster dose to people under 50 amid a steady rise in cases, with the United States seeing a threefold increase over the past month.

The U.S. Food and Drug Administration had in late March authorized a second booster dose of the Moderna and Pfizer/BioNTech SE vaccines for people aged 50 and older, citing data showing waning immunity and the risks posed by Omicron variants of the virus.

"With regard to a fourth dose for those under the age of 50, that is going to require action from the FDA, and we're in conversations there," U.S. Centers for Disease Control and Prevention Director Rochelle Walenksy said on Wednesday.

Cases have steadily risen over the past five weeks, Walensky said at a White House briefing, with the the current seven-day average of daily cases rising 26% from the previous week to 94,000 cases per day and up threefold over the last month. The seven-day average for hospitalizations was up 19% to about 3,000 per day and the average for deaths was 275 per day, she said.

"We of course must remember that each person lost to COVID-19 is a tragedy and that nearly 300 deaths a day is still far too many," said Walensky. (Reporting by Ahmed Aboulenein and Jeff Mason; Additional reporting by Susan Heavey; Editing by Alison Williams)

© Reuters 2022
All news about MODERNA, INC.
07/01INSIDER SELL : Moderna
06/30Moderna Files For Canadian Regulatory Approval Of New COVID-19 Booster
06/30U.S. FDA to use existing Omicron booster data to review shots targeting new subvariants..
06/30US FDA wants COVID boosters targeting Omicron BA.4, BA.5 subvariants
06/30Tweaked COVID boosters in US must target newer omicron types
06/30Moderna Seeks Health Canada Nod For New Double-Protection Covid-19 Booster - Global New..
06/30COVID SCIENCE-Pausing methotrexate improves booster response; first-trimester of pregna..
06/29BioNTech, Pfizer to starting testing universal coronavirus vaccine in H2
06/29Taiwan to receive first doses of Novavax COVID vaccine this week
06/28Pfizer, Moderna to be ready with BA.1-specific COVID boosters
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 079 M - -
Net income 2022 11 509 M - -
Net cash 2022 18 531 M - -
P/E ratio 2022 5,50x
Yield 2022 -
Capitalization 59 644 M 59 644 M -
EV / Sales 2022 1,86x
EV / Sales 2023 3,77x
Nbr of Employees 2 700
Free-Float 90,6%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 149,95 $
Average target price 213,67 $
Spread / Average Target 42,5%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.83%40 011
SEAGEN INC.16.50%33 154
CELLTRION, INC.-9.34%19 031